Mammalian Cell Culture Market Size, Share, Top Key Players, Growth, Trend and Forecast Till 2030
Rising demand for vaccines against coronavirus and other diseases is a key factor driving market revenue growth
According to the most recent analysis by Emergen Research, the global market for mammalian cell culture reached USD 1.90 billion in 2021 and is anticipated to grow at a rate of 12.13% over the projected period. Increasing use of gene therapy techniques for the treatment of genetic abnormalities and rising demand for vaccinations against the coronavirus and other diseases are expected to fuel market revenue growth between 2022 and 2030. Numerous biopharmaceutical products, such as vaccines, monoclonal antibodies, recombinant proteins, and hormones, are produced using mammalian cell cultures. Increased production of coronavirus vaccines and monoclonal antibodies against the virus, which are made using mammalian cell culture methods, is a result of the disease’s rising prevalence.
Between 2022 and 2030, it is anticipated that rising rates of viral illnesses including the mumps, rubella, and the recent measles outbreak in certain parts of emerging countries would further drive market revenue growth. Additionally, therapeutic recombinant proteins against autoimmune and hereditary illnesses including multiple sclerosis and rheumatoid arthritis are produced using mammalian cell lines. The human IgG antibody MOR103mAb, which targets the disease-causing colony-stimulating factor, is currently undergoing clinical testing. Mammalian cell lines are being used to create MAbs that will fight cancer, asthma, TB, and other autoimmune illnesses like psoriatic arthritis and ankylosing spondylitis. This is anticipated to accelerate market revenue growth between 2022 and 2030.
Get a sample of the report https://www.emergenresearch.com/request-sample/1042
One of the main factors anticipated to restrain market revenue growth to some extent is worries about endotoxin contamination of mammalian cell lines, which includes both biological contaminants like bacteria, yeast, mycoplasma, and viruses as well as chemicals like endotoxins. Since bacterial cell lines can endure mechanical agitation, mammalian cell cultures cannot because they are shear sensitive. As a result, there are less options to scale up mammalian cell-based product bioprocessing. Additional obstacles that are anticipated to impede market revenue growth include high costs and strict restrictions. Due to the low cost, simplicity of availability, uniform quantity of media ingredients, and the range of cell lines that may be cultivated on the media, the revenue from the traditional media category is anticipated to account for the greatest revenue share throughout the projection period.
During the forecast period, Europe is anticipated to have a considerably higher revenue share in the mammalian cell culture market. One of the main factors propelling the market’s revenue growth in Europe is the development of bioprocessing techniques with expanded chances for scaling up mammalian cell culture systems. A further element boosting market revenue growth is the rising number of clinical and pre-clinical trials being carried out in these nations. This MoU is anticipated to pave the way for SNUBH to investigate GE Healthcare’s Edison Digital Health Platform and associated services. The Edison Digital Health Platform will be completely launched for Korean developers for the first time at this time. The platform is the application hosting and development platform for GE Healthcare.
Some major companies in the global market report include Merck KGaA, ThermoFisher Scientific Inc., Cytiva, Novartis AG, FUJIFILM Irvine Scientific, Agilent Technologies, Inc., Lonza Group AG, GE Healthcare, PromoCell GmbH, and Horizon Discovery Ltd.
Emergen Research has segmented the global mammalian cell culture market on the basis of media, cell line, application, end-use, and region:
- Media Outlook (Revenue, USD Billion, 2019–2030)
- Classical Media
- Serum-Free Media
- Cell Line Outlook (Revenue, USD Billion, 2019–2030)
- Application Outlook (Revenue, USD Billion, 2019–2030)
- Monoclonal Antibodies
- Tissue Engineering
- Recombinant Cell Therapeutic Proteins
- Cytotoxic Testing
- End-Use Outlook (Revenue, USD Billion, 2019–2030)
- Biopharmaceutical Industry
- Academic and Research Laboratories
- Drug Test Laboratories
To know more about the report, visit https://www.emergenresearch.com/industry-report/mammalian-cell-culture-market
- Regional Outlook (Revenue, USD Billion, 2019–2030)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
- North America
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]